The Effect Of Preoperative Intravesical Instilation Of Pirarubicin To The Prognosis Of Non Muscle-invasive Bladder Cancer

Objective:To evaluate the impact of preoperative intravesical instillation of pirarubicin to the prognosis of patients with non muscle-invasive bladder cancer.Methods:A total of 135 cases of non-muscle invasive bladder cancer were collected, TUR - BT therapy was performed in all cases. According to include and exclude standards,120 cases finally been collected.The perfusion group of 40 cases,30 minutes before operation, intravesical instillation of pirarubicin (pirarubicin 30 mg + 5% GS 50ml) was performed in the perfusion group (40 cases). the control group 80 cases without perfusion before operation; Both the perfusion group and the control group were given intravesical instillation of pirarubicin from the beginning of 2 weeks after the operation, once a week for 8 weeks. And then the patient was given once a month to 1 year after the operation. All patients were followed up for 1 years after operation,every 3 months take cystoscopy to observe the tumor recurrence, progress.Results:In the perfusion and control group,the total recurrence rate respectively were 17.5% and 35.0%.The total progress rate respectively were 5% and 7.5%.In the middle risk group according to the EORTC scale system, The recurrence rate respectively were 14.8% and 36.7%.The difference of the progress between the two groups have no statistical significance.In the total recurrence rate and the middle risk group according to the EORTC scale system,the the difference between the two groups have statistical significance.Conclusion:Preoperative intravesical instillation of pirarubicin can reduce the recurrence rate 1 years after operation of non muscle-invasive bladder cancer, especially in patients with middle risk group according to the EORTC scale system, is a effective methods to reduce recurrence rate of the non-muscle invasive bladder cancer.